1. Home
  2. USNA vs GOSS Comparison

USNA vs GOSS Comparison

Compare USNA & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • USNA
  • GOSS
  • Stock Information
  • Founded
  • USNA 1992
  • GOSS 2015
  • Country
  • USNA United States
  • GOSS United States
  • Employees
  • USNA N/A
  • GOSS N/A
  • Industry
  • USNA Medicinal Chemicals and Botanical Products
  • GOSS Biotechnology: Pharmaceutical Preparations
  • Sector
  • USNA Health Care
  • GOSS Health Care
  • Exchange
  • USNA Nasdaq
  • GOSS Nasdaq
  • Market Cap
  • USNA 565.5M
  • GOSS 585.9M
  • IPO Year
  • USNA 1996
  • GOSS 2019
  • Fundamental
  • Price
  • USNA $20.88
  • GOSS $2.19
  • Analyst Decision
  • USNA Hold
  • GOSS Strong Buy
  • Analyst Count
  • USNA 1
  • GOSS 6
  • Target Price
  • USNA $36.00
  • GOSS $8.60
  • AVG Volume (30 Days)
  • USNA 189.4K
  • GOSS 3.6M
  • Earning Date
  • USNA 10-21-2025
  • GOSS 11-06-2025
  • Dividend Yield
  • USNA N/A
  • GOSS N/A
  • EPS Growth
  • USNA N/A
  • GOSS N/A
  • EPS
  • USNA 1.80
  • GOSS N/A
  • Revenue
  • USNA $899,221,000.00
  • GOSS $40,237,000.00
  • Revenue This Year
  • USNA $13.94
  • GOSS N/A
  • Revenue Next Year
  • USNA $7.95
  • GOSS $34.10
  • P/E Ratio
  • USNA $11.63
  • GOSS N/A
  • Revenue Growth
  • USNA 2.75
  • GOSS N/A
  • 52 Week Low
  • USNA $19.88
  • GOSS $0.66
  • 52 Week High
  • USNA $41.84
  • GOSS $3.60
  • Technical
  • Relative Strength Index (RSI)
  • USNA 23.23
  • GOSS 39.68
  • Support Level
  • USNA $19.88
  • GOSS $2.25
  • Resistance Level
  • USNA $21.46
  • GOSS $2.61
  • Average True Range (ATR)
  • USNA 0.97
  • GOSS 0.18
  • MACD
  • USNA -0.55
  • GOSS -0.05
  • Stochastic Oscillator
  • USNA 12.26
  • GOSS 2.27

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Share on Social Networks: